肿瘤细胞治疗研究
英文原题：Early Hyperprogression of Rhabdomyosarcoma Detected by (18) F-FDG PET/CT Three Weeks after CAR-T Treatment.
CAR-T 细胞治疗已广泛应用于血液系统恶性肿瘤的治疗，其应用已逐渐扩展到实体瘤的研究和治疗中。
CAR-T 细胞治疗已广泛用于血液系统恶性肿瘤的治疗，其应用也逐渐扩展至实体瘤的研究和治疗。然而，CAR-T治疗后可能出现非常规类型的反应，如超进展，导致不良结局。在此，我们报告一例13岁青少年男孩，患有复发难治性横纹肌肉瘤，在CAR-T治疗（靶点：B7H3和CD171）后3周出现早期超进展，通过氟-18氟脱氧葡萄糖（18 F-FDG）正电子发射断层扫描（PET）/计算机断层扫描（CT）检测发现。患者最终接受了截肢。应关注CAR-T治疗后早期超进展的可能性，18 F-FDG PET/CT在早期评估免疫治疗反应方面具有绝对优势。
Chimeric antigen receptor T-cell (CAR-T) treatment has been widely used in the treatment of hematological malignancies, and its application has been gradually expanded to the research and treatment of solid tumors. However, unconventional types of response may occur after CAR-T treatment, such as hyperprogression, resulting in terrible outcomes. Here, we report the case of a 13-year-old adolescent boy with relapsed and refractory rhabdomyosarcoma who developed early hyperprogression 3 weeks after CAR-T treatment (target: B7H3 and CD171), which was detected by fluorine-18 fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET)/computed tomography (CT). The patient eventually underwent amputation. Attention should be paid to the possibility of early hyperprogression after CAR-T treatment, and 18 F-FDG PET/CT has an absolute advantage in early evaluating treatment response to immunotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
